Phase II Trial of In Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 Planned End Date changed from 1 Mar 2020 to 1 Jul 2020.